Skip to content
CancerIndex

Publication

First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.

Yaning Yang, Wenxin Jiang, Guangjian Yang, Weihua Li, Junling Li, Xuezhi Hao, Puyuan Xing, Siyu Lei, Fang Wei, Linyan Tian, Haiyan Xu, Yan Wang

Lung cancer (Amsterdam, Netherlands)Oct 1, 2026PMID 42691829doi:10.1016/j.lungcan.2026.109589 Journal ArticleClinical Trial, Phase IIpubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Although emerging agents have broadened the therapeutic landscape for non-small cell lung cancer (NSCLC) harboring HER2 alterations, effective and accessible first-line therapy remains limited. METHODS: In this single-arm, phase II trial, treatment-naïve patients with stage IIIB-IV…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.